The aim of this work was to quantify the uptake of 18F-BMS-986192, a programmed cell
death ligand 1 (PD-L1) adnectin PET tracer, in patients with non–small cell lung cancer. To …

68Ga-NOTA-WL12 is a peptide-based PET imaging agent. We conducted a first-in-human
study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation …

Rationale and Objectives To explore the potential value of radiomic features-derived
approach in assessing PD-L1 expression status in nonsmall cell lung cancer (NSCLC) …

Background In recent years, immune checkpoint inhibitor (ICI) therapy has greatly changed
the treatment prospects of patients with non-small cell lung cancer (NSCLC). Among the …

Abstract Purpose Anti-PD-1/PD-L1 blockade can restore tumour-specific T-cell immunity and
is an emerging therapy in non-small-cell lung cancer (NSCLC). We investigated the …

Purpose Despite remarkable clinical responses and prolonged survival across several
cancers, not all patients benefit from PD-1/PD-L1 immune checkpoint blockade. Accordingly …

This positron emission tomography (PET) study was designed to compare 2-[fluorine-18]
fluoro-2-deoxy-D-glucose (FDG) kinetic parameters of tumours derived from imaging frames …

Although immunotherapy through programmed death 1/programmed death ligand 1 (PD-
1/PD-L1) checkpoint blockade has shown impressive clinical outcomes, not all patients …

Programmed cell death-ligand 1 (PD-L1) expression is commonly observed in non-small
cell lung cancer (NSCLC). The prognostic value of PD-L1 expression and the maximum …

18F-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1)
tracer, was developed to noninvasively determine whole-body PD-L1 expression by PET …